The 83 horses included both sexes (53 females and 30 males ). The study protocol and care of the horses were approved by the Cornell University College of Veterinary Medicine Institutional Animal Care and Use Committee. Horses-Eighty-three clinically normal horses that were either part of a teaching herd at Cornell University's Equine Research Park or admitted for performance evaluation at the equine performance testing center were included in the study. If the point-of-care analyzer could be used to detect changes in plasma cTnI concentration in sick horses, we would anticipate that its application would be of benefit in the evaluation of myocardial injury in horses in field settings. Values in clinically normal horses were acquired to establish a reference range for plasma equine cTnI concentration determined by use of the point-of-care analyzer. The purpose of the study reported here was to compare cTnI concentrations determined by use of a point-of-care analyzer with values determined by use of a bench-top immunoassay d in plasma samples obtained from clinically normal horses and horses with experimentally induced cardiac disease. 22 However, it is unknown whether this point-of-care analyzer would accurately determine circulating cTnI concentrations in horses. More recently, a point-of-care analyzer c has become available and was validated for measurement of whole blood cTnI concentration in humans. 21 Various benchtop methods were used for the analysis of cTnI concentrations in those studies. 8–10, a Data regarding circulating cTnI concentrations in horses are limited except for reports of assessments made in Thoroughbreds in training or on pasture 11–13 and in a few cases of myocarditis, 14 cantharidin toxicosis, 15 ruptured aortic jet lesions, 16 snake envenomation, b airway obstruction, 17 babesiosis, 18 electrical cardioconversion, 19 sepsis, 20 and monensin intoxication. 1–3 Blood concentrations of cTnI in clinically normal cats and dogs have been reported as well as cTnI concentrations in cats and dogs with gastric dilatation and volvulus, 4 congestive heart failure, 5 neoplasia (and receiving chemotherapy), 6 heatstroke, 7 cardiomyopathy, and pericardial disease. In patients with myocardial infarction, sepsis, or traumatic myocardial injury, assessment of circulating cTnI concentration is used to aid diagnosis and provide prognostic information. Peak analyzer-determined plasma cTnI concentrations in monensin-treated horses ranged from 0.08 to 3.68 ng/mL.Ĭonclusions and Clinical Relevance-In horses with and without experimentally induced cardiac disease, the point-of-care analyzer and bench-top immunoassay provided similar values of plasma cTnI concentration.Ĭardiac troponin is a highly sensitive and specific biomarker of myocardial injury in humans. Following monensin treatment in 5 horses, increases in plasma cTnI concentration determined by use of the 2 methods were highly correlated (Pearson correlation, 0.83). Results-The analyzer-specific reference range for plasma cTnI concentration in clinically normal horses was 0.0 to 0.06 ng/mL. In 6 horses, blood samples were also collected at various time points after administration of a single dose of monensin (1.0 to 1.5 mg/kg) via nasogastric intubation plasma cTnI concentration in those samples was assessed by use of both methods. All 83 samples were used to establish an analyzer-specific reference range for plasma cTnI concentration in clinically normal horses. Procedures-A blood sample was collected from each of the 83 clinically normal horses to provide plasma for analysis by use of the point-of-care analyzer some of the same samples were also analyzed by use of the immunoassay. Objective-To compare cardiac troponin I (cTnI) concentrations determined by use of a point-of-care analyzer with values determined by use of a bench-top immunoassay in plasma samples obtained from clinically normal horses with and without experimentally induced cardiac disease, and to establish a reference range for plasma equine cTnI concentration determined by use of the point-of-care analyzer.Īnimals-83 clinically normal horses, 6 of which were administered monensin to induce cardiac disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |